Abstract
Abnormalities in glycosphingolipid (GSL) biosynthesis have been implicated in the oncogenesis and malignancy of brain tumours. GSLs comprise the gangliosides and the neutral GSLs and are major components of the cell surface glycocalyx. N -butyldeoxynojirimycin (N B-DNJ) is an imino sugar that inhibits the glucosyltransferase catalysing the first step in GSL biosynthesis. The influence of N B-DNJ was studied on the growth and ganglioside composition of two 20-methylcholanthrene-induced experimental mouse brain tumours, EPEN and CT-2A, which were grown in vitro and in vivo. N B-DNJ (200 μM) inhibited the proliferation of the EPEN and CT-2A cells by 50%, but did not reduce cell viability. The drug, administered in the diet (2400 mg kg–1) to adult syngeneic C57BL/6 mice, reduced the growth and ganglioside content of subcutaneous and intracerebral EPEN and CT-2A tumours by at least 50% compared to the untreated controls. N B-DNJ treatment also shifted the relative distribution of tumour gangliosides in accordance with the depletion of metabolic substrates. Side effects of N B-DNJ treatment were generally mild and included reductions in body and spleen weights and intestinal distension. We conclude that N B-DNJ may inhibit tumour growth through an effect on ganglioside biosynthesis and may be useful as a new chemotherapy for brain tumours. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alessandri G, Cornaglia Ferraris P and Gullino PM (1997) Angiogenic and angiostatic microenvironment in tumors – role of gangliosides. Acta Oncol 36: 383–387
Andersson U, Butters TD, Dwek RA and Platt FM (2000) N- butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol 59: 821–829
Bai H and Seyfried TN (1997) Influence of ganglioside GM3 and high density lipoprotein (HDL) on the cohesion of mouse brain tumor cells. J Lipid Res 38: 160–172
Berra B, Colombo I, Monteggia E, Montorfano G, Moretti S, Rapelli S and Sottocornola E (1997) Glycosphingolipid expression in solid tumours and transformed cell lines. Indian J Biochem Biophys 34: 170–177
Brigande JV, Platt FM and Seyfried TN (1998) Inhibition of glycosphingolipid biosynthesis does not impair growth or morphogenesis of the postimplantation mouse embryo. J Neurochem 70: 871–882
Chang F, Li R and Ladisch S (1997) Shedding of gangliosides by human medulloblastoma cells. Exp Cell Res 234: 341–346
Cotterchio M and Seyfried TN (1993) The influence of ImuVert, a biological response modifier, on the growth and ganglioside composition of murine neural tumors. Mol Chem Neuropathol 20: 163–172
Cotterchio M and Seyfried TN (1994) Serum gangliosides in mice with metastatic and non-metastatic brain tumors. J Lipid Res 35: 10–14
Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D and Zimran A (2000) Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355: 1481–1485
Davis FG, McCarthy BJ, Freels S, Kupelian V and Bondy ML (1999) The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer 85: 485–491
Ecsedy JA, Yohe HC, Bergeron AJ and Seyfried TN (1998) Tumor-infiltrating macrophages contribute to the glycosphinglipid composition of brain tumors. J Lipid Res 39: 2218–2227
Ecsedy JA, Holthaus KA, Yohe HC and Seyfried TN (1999) Expression of mouse sialic acid on gangliosides of a human glioma grown as a xenograft in SCID mice. J Neurochem 73: 254–259
El-Abbadi M and Seyfried TN (1994) Influence of growth environmental on the ganglioside composition of an experimental mouse brain tumor. Mol Chem Neuropathol 21: 273–285
Fathallah-Shaykh H (1999) New molecular strategies to cure brain tumors. Arch Neurol 56: 449–453
Fischl MA, Resnick L, Coombs R, Kremer AB, Pottage JC, Jr Fass RJ, Fife KH, Powderly WG, Collier AC, Aspinall RL, Smith SL, Kowalski KG and Wallemark C-B (1994) The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200–500 CD4 cells/mm3. J Acquir Immune Defic Syndr 7: 139–147
Flavin HJ, Wieraszko A and Seyfried TN (1991) Enhanced aspartate release from hippocampal slices of epileptic (El) mice. J Neurochem 56: 1007–1011
Folch J, Lees M and GH Sloane-Stanley (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497–509
Hakomori S (1996) Tumor malignancy defined by aberrant glycosylation and sphingo (glyco) lipid metabolism. Cancer Res 56: 5309–5318
Harbaugh KS and Black PM (1998) Strategies in the surgical management of malignant gliomas. Semin-Surg-Oncol 14: 26–33
Jeyakumar M, Butters TD, Cortina-Borja M, Hunnam V, Proia RL, Perry VH, Dwek RA and Platt FM (1999) Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci USA 96: 6388–6393
Karlsson GB, Butters TD, Dwek RA and Platt FM (1993) Effects of the imino sugar N-butyldeoxynojirimycin on the N-glycosylation of recombinant gp120. J Biol Chem 268: 570–576
Kemp RB (1968) Effect of the removal of cell surface sialic acids on cell aggregation in vitro. Nature 218: 1255–1256
Liu YY, Han TY, Giuliano AE and Cabot MC (1999) Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 274: 1140–1146
Manfredi MG, Lim S, Claffey KP and Seyfried TN (1999) Gangliosides influence angiogenesis in an experimental mouse brain tumor. Cancer Res 59: 5392–5397
Merzak A, Koochekpour S, McCrea S, Roxanis Y and Pilkington GJ (1995) Gangliosides modulate proliferation, migration, and invasiveness of human brain tumor cells in vitro. Mol Chem Neuropathol 24: 121–135
Platt FM and Butters TD (1995) Inhibitors of glycosphingolipid biosynthesis. Trends Glycosci Glycotech 7: 495–511
Platt FM and Butters TD (1998) New therapeutic prospects for the glycosphingolipid lysosomal storage diseases. Biochem Pharmacol 56: 421–430
Platt FM, Neises GR, Dwek RA and Butters TD (1994) N- butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 269: 8362–8365
Platt FM, Neises GR, Reinkensmeier G, Townsend MJ, Perry VH, Proia RL, Winchester B, Dwek RA and Butters TD (1997a) Prevention of lysosomal storage in Tay-Sachs mice treated with N- butyldeoxynojirimycin. Science 276: 428–431
Platt FM, Reinkensmeier G, Dwek RA and Butters TD (1997b) Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin. J Biol Chem 272: 19365–19372
Prados MD and Levin V (2000) Biology and treatment of malignant glioma. Semin Oncol 27: 1–10
Radin NS (1999) Chemotherapy by slowing glucosphingolipid synthesis. Biochem Pharmacol 57: 589–595
Ranes MK, Manfredi MG, El-Abbadi MM, Platt FM and Seyfried TN (2000) N-Butyldeoxynojirmycin reduces growth rate and ganglioside content in mouse brain tumors. Proc Amer Assoc Cancer Res 41: 258
Rubin R, Sutton CH and Zimmerman HM (1968) Experimental ependymoblastoma (fine structure). J Neuropathol Exp Neurol 27: 421–438
Sandhoff K and van Echten G (1994) Ganglioside metabolism: enzymology, topology and regulation. Prog Brain Res 101: 17–29
Schmidt CW (1998) Childhood cancer: A growing problem. Environ Health Perspect 106: A18–A23
Seyfried TN (2001) Perspectives on brain tumor formation involving macrophages, glia, and neural stem cells. Persp Biol Med, in press
Seyfried TN, Glaser GH and Yu RK (1978) Cerebral, cerebellar, and brain stem gangliosides in mice susceptible to audiogenic seizures. J Neurochem 31: 21–27
Seyfried TN, Yu RK, Saito M and Albert M (1987) Ganglioside composition of an experimental mouse brain tumor. Cancer Res 47: 3538–3542
Seyfried TN, El-Abbadi M and Roy ML (1992) Ganglioside distribution in murine neural tumors. Mol Chem Neuropathol 17: 147–167
Seyfried TN, Novikov AM, Irvine RA and Brigande JV (1994) Ganglioside biosynthesis in mouse embroys: sialyltransferase IV and the asialo pathway. J Lipid Res 35: 993–1001
Seyfried TN, El-Abbadi M, Ecsedy JA, Bai HW and Yohe H (1996) Influence of host cell infiltration on the glycolipid content of mouse brain tumors. J Neurochem 66: 2026–2033
Seyfried TN, El-Abbadi M, Ecsedy JA, Griffin ME and Yohe HC (1998) Ganglioside composition of a mouse brain tumor grown in the severe combined immunodeficiency (SCID) mouse. Mol Chem Neuropathol 33: 27–37
Shapiro WR (1999) Current therapy for brain tumors: back to the future. Arch Neurol 56: 429–432
Svennerholm L (1957) Quantitative estimation of sialic acids II. A colorimetric resorcinol-hydrochloric acid method. Biochim Biophys Acta 24: 604–611
Weindruch R and Walford RL (1988) The retardation of aging and disease by dietary restriction. Thomas: Springfield, IL.
Yu RK and Ledeen RW (1970) Gas–liquid chromatographic assay of lipid-bound sialic acids: measurement of gangliosides in brain of several species. J Lipid Res 11: 506–516
Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S and Levin VA (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588–593
Zeng G, Gao L, Birkle S and Yu RK (2000) Suppression of ganglioside GD3 expression in a rat F-11 tumor cell line reduces tumor growth, angiogenesis, and vascular endothelial growth factor production. Cancer Res 60: 6670–6676
Zimmerman HM (1982) Production of brain tumors with aromatic hydrocarbons. Ann N Y Acad Sci 381: 320–324
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ranes, M., El-Abbadi, M., Manfredi, M. et al. N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours. Br J Cancer 84, 1107–1114 (2001). https://doi.org/10.1054/bjoc.2000.1713
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1713
Keywords
This article is cited by
-
Nature-inspired male contraceptive and spermicidal products
Phytochemistry Reviews (2021)
-
Effect of treatment with baicalein on the intracerebral tumor growth and survival of orthotopic glioma models
Journal of Neuro-Oncology (2015)
-
Tumor carbohydrate antigens and strategies to develop cancer vaccines and drugs
Wuhan University Journal of Natural Sciences (2013)
-
Caloric restriction reduces edema and prolongs survival in a mouse glioma model
Journal of Neuro-Oncology (2013)
-
Therapeutic Effects of Stem Cells and Substrate Reduction in Juvenile Sandhoff Mice
Neurochemical Research (2012)